RXO (RXO) Q3 Spot Rate Index Reaches 37.9%, Highest Since 2021

RXO's Curve spot-rate index rose to 37.9% in Q3, the highest since 2021, up from 32.4% in Q2. As of Nov. 13, the index showed a sequential decline but still indicated Q4 inflation. RXO noted this as an operational update, not a financial-results disclosure.

Original reporting
Published Nov 17, 2026, 1:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 17, 2026, 1:37 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
RXO (RXO) Q3 Spot Rate Index Reaches 37.9%, Highest Since 2021 — source image
Decision brief

The 30-second read

$RXOBullishLow
01

Why it matters

Traders may use the index as a leading indicator for pricing conditions, but without disclosed linkage to RXO’s realized rates, it is more of a sentiment input than a decision-grade catalyst.

02

Market read

A higher spot-rate index can support expectations for better pricing, but the article does not provide a direct financial or guidance impact.

03

What to watch

The article does not provide RXO-specific conversion metrics (bookings, utilization, realized rates), so the market may discount the index as a leading but unconfirmed indicator.

Relevance 4/10Novelty 4/10Timing: published mid-day, immediate read-through to RXO pricing conditions for Q4

Background

The article attributes the update to RXO’s Curve spot-rate index, describing its sequential rise through Q3 and tracking toward Q4 inflation.

Company-level read

Ticker impact

$RXOBullishMedium confidence
Context

RXO reports its Curve spot-rate index ended Q3 at 37.9%, up from 32.4% in Q2 and highest since 2021, signaling spot-rate inflation.

Expected impact

Likely modest positive bias as traders read the index as supportive of near-term pricing, though follow-through depends on whether it translates into RXO financials.

Evidence & confidence

The piece is an operational market update with a clear directional index move, but it does not quantify how RXO’s revenue, utilization, or margins will change.

Market effects

If spot rates are rising broadly, it can improve sentiment across transportation and logistics operators exposed to spot pricing.

No specific regional demand signal is provided beyond the index trend.

No explicit global macro linkage is stated beyond the index being on pace for Q4 inflation.

Counterpoint

Spot-rate index strength may not translate into RXO earnings if contract mix, capacity constraints, or hedging offsets the pricing tailwind.

Key entities

  • RXO

    Operator reporting Curve spot-rate index ended Q3 at 37.9%, highest since 2021.

Related articles

$RXOMedAI 8/10

RXO stock holds at StoneX as freight rates improve ahead of CHRW deal

StoneX reiterated a Hold rating on RXO, Inc. (NYSE:RXO) after its Q3 adjusted EBITDA of $51M exceeded estimates. RXO's truckload gross profit and margins improved, with spot rates and contract pricing supporting brokerage margins. RXO's stock has surged 120% YTD. C.H. Robinson's $5.8B acquisition of RXO is pending, with mixed analyst reactions on ratings and price targets.

$RXOHigh

RXO’s earnings still coming out, had solid profitable quarter

RXO reported a profitable third quarter with adjusted EBITDA of $51 million, exceeding its forecast. Gross margin was 14.6%, up from Q2 but down from a year ago. CEO Drew Wilkerson highlighted momentum. Brokerage and truckload volumes increased, with a shift toward the spot market. LTL and Last Mile segments also saw growth. RXO's founder supports its acquisition by C.H. Robinson (CHRW).

$CHRWMedAI 8/10

C.H. Robinson leaders tackle RXO friction concerns

C.H. Robinson executives addressed concerns about operational overlap from the $5.8B RXO acquisition, citing manageable overlap and synergies. They emphasized Lean AI strategies for integration. Q3 2023 earnings showed net income of $198.5M and revenue of $5.36B, up 29.5% YoY. North American Surface Transportation and Global Forwarding segments both reported revenue and income growth.

$RXOMedAI 8/10

RXO (NYSE:RXO) exceeds Q3 2026 expectations

RXO reported Q3 2026 revenue of $1.87B, beating estimates by 2.6% and growing 31.7% year-on-year. Adjusted EPS was $0.09, a 20% beat, with adjusted EBITDA at $51M, a 15.1% beat. Operating margin improved to 0.9% from -0.5% last year, while free cash flow margin remained at 0.6%. Sales volumes increased 2% year-on-year.